Nasdaq Investment Intelligence Content Hub When Will Smaller Biotech Firms Get Their Big Break? By Tom LydonAugust 25, 2021
Featured Biotech ETFs Are Already Benefitting from Pfizer Vaccine’s Full Approval By Ian YoungAugust 23, 2021
Nasdaq Investment Intelligence Content Hub Bet on Biotech Small Caps to Bounce Back By Tom LydonAugust 19, 2021
Nasdaq Investment Intelligence Content Hub Why Small Cap Biotech ETFs Are Still Brilliant Bets By Tom LydonMarch 26, 2021
Innovative ETFs Content Hub Consider Smaller Biotech ETFs as Big Pharma Goes Shopping in 2021 By Max ChenDecember 31, 2020
Nasdaq Investment Intelligence Content Hub Young But Hungry: A New Defiance ETF is Defying Expectations By Tom LydonNovember 13, 2020
Nasdaq Investment Intelligence Content Hub Small-Cap Biotechnology ETF Brings Big Opportunity By Tom LydonSeptember 9, 2020
ETF of the Week ETF of the Week: Defiance Nasdaq Junior Biotechnology ETF (IBBJ) By Aaron NeuwirthAugust 20, 2020
Nasdaq Investment Intelligence Content Hub A Junior Biotech ETF With Home Run Potential By Todd ShriberAugust 14, 2020
Nasdaq Investment Intelligence Content Hub New Biotech ETF Taps Into Small But Mighty Theme By Tom LydonAugust 6, 2020
Nasdaq Investment Intelligence Content Hub Defiance Debuts Nasdaq Junior Biotechnology ETF (IBBJ) By Brenton GarenAugust 4, 2020
